Assertio Therapeutics Valuation
| ASRT Stock | USD 0.80 0.02 2.44% |
Today, the firm appears to be fairly valued. Assertio Therapeutics shows a prevailing Real Value of $0.82 per share. The current price of the firm is $0.8. Our model approximates the value of Assertio Therapeutics from analyzing the firm fundamentals such as Return On Equity of -0.38, profit margin of (0.37) %, and Current Valuation of 29.58 M as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Assertio Therapeutics' price fluctuation is extremely dangerous at this time. Calculation of the real value of Assertio Therapeutics is based on 3 months time horizon. Increasing Assertio Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Assertio Therapeutics' intrinsic value may or may not be the same as its current market price of 0.80, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.8 | Real 0.82 | Hype 0.8 | Naive 0.76 |
The intrinsic value of Assertio Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Assertio Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Assertio Therapeutics helps investors to forecast how Assertio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Assertio Therapeutics more accurately as focusing exclusively on Assertio Therapeutics' fundamentals will not take into account other important factors: Assertio Therapeutics Total Value Analysis
Assertio Therapeutics is presently projected to have valuation of 29.58 M with market capitalization of 79.31 M, debt of 39.77 M, and cash on hands of 52.26 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Assertio Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
29.58 M | 79.31 M | 39.77 M | 52.26 M |
Assertio Therapeutics Investor Information
About 27.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. Assertio Therapeutics has Price/Earnings To Growth (PEG) ratio of 1.5. The entity recorded a loss per share of 0.45. The firm had not issued any dividends in recent years. Assertio Therapeutics had 1:4 split on the 18th of May 2021. Based on the key indicators related to Assertio Therapeutics' liquidity, profitability, solvency, and operating efficiency, Assertio Therapeutics is not in a good financial situation at the moment. It has a very high risk of going through financial straits in November.Assertio Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Assertio Therapeutics has an asset utilization ratio of 43.89 percent. This implies that the Company is making $0.44 for each dollar of assets. An increasing asset utilization means that Assertio Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Assertio Therapeutics Ownership Allocation
Assertio Therapeutics holds a total of 96.24 Million outstanding shares. Almost 70.62 percent of Assertio Therapeutics outstanding shares are held by general public with 2.51 (percent) owned by insiders and only 26.87 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Assertio Therapeutics Profitability Analysis
The company reported the previous year's revenue of 124.96 M. Net Loss for the year was (21.58 M) with profit before overhead, payroll, taxes, and interest of 77.38 M.About Assertio Therapeutics Valuation
The stock valuation mechanism determines Assertio Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Assertio Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Assertio Therapeutics. We calculate exposure to Assertio Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Assertio Therapeutics's related companies.Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois. Assertio Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 19 people.
Assertio Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Assertio Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 95.3 M | |
| Quarterly Earnings Growth Y O Y | -0.188 | |
| Forward Price Earnings | 14.9925 |
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.